The Gap Between LIMS Capabilities and QC Microbiology Needs

whitePaper | November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

whitePaper | February 24, 2022

Filamentous fungi of the phylum Basidiomycota are considered as an attractive source for the biotech‑ nological production of composite materials. The ability of many basidiomycetes to accept residual lignocellulosic plant biomass from agriculture and forestry.

whitePaper | December 16, 2022

Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally. However, Asia Pacific (APAC) has demonstrated the most growth in CGT developers of any other region, with a rise of 10% in H1 2022 compared to 2021.1

whitePaper | August 7, 2022

The number of biologic new molecular entities approved by the FDA has increased over the last five years indicates a growing focus on biosimilar.

whitePaper | December 20, 2022

The current processing paradigm of large manufacturing facilities dedicated to singleproduct production is no longer an effective approach for best manufacturing practices.